STOCKS TELEGRAPH

Tag: NASDAQ:ATHE

  • Alterity (ATHE) Sees Major Stock Rally After Clinical Success

    Alterity (ATHE) Sees Major Stock Rally After Clinical Success

    Following the release of encouraging clinical trial data, Alterity Therapeutics Limited (NASDAQ: ATHE) stock value has significantly increased. ATHE shares have risen 47.42% to $4.29 as of the most recent market check.

    Alterity Unveiled Breakthrough in MSA Treatment

    The ATH434-201 Phase 2 clinical trial, a randomized, double-blind, placebo-controlled study evaluating ATH434 in individuals with early-stage multiple system atrophy (MSA), provided Alterity (ATHE) with promising topline findings.

    A key instrument for assessing disability in daily activities impacted by MSA, the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, was found to be significantly improved by ATH434 in both clinical and statistical analyses. After 52 weeks, the drug postponed clinical development by 29% at the 75 mg level and 48% at the 50 mg dose as compared to a placebo.

    Biomarker and MRI Evidence Support Drug Efficacy

    In this uncommon, fast-progressing illness, ATH434 has shown a notable slowdown of clinical development along with an exceptional safety profile. These findings suggest that ATH434’s targeted iron engagement may really have a disease-modifying impact, considering there are currently no authorized medications that delay the course of MSA.

    ATHE On Pathway Toward FDA Engagement

    With no currently approved treatments capable of slowing MSA progression, these findings suggest that ATH434 may offer a transformative disease-modifying effect. Alterity Therapeutics has confirmed its intent to engage with the U.S. Food and Drug Administration (FDA) to accelerate development plans based on these promising results.

    This breakthrough has implications for developing disease-modifying treatments for both orphan diseases like MSA and major neurodegenerative disorders, offering new hope for patients facing these debilitating conditions.

    Market Performance and Analyst Ratings

    Following these promising clinical trial results, Alterity Therapeutics has garnered increased attention from analysts and investors. ATHE stock has an ST score of 43 on our screener, with analysts assigning a Strong Buy rating. Investors seeking insights into comparable biotechnology stocks can explore our screener link for further analysis.

  • Alterity (ATHE) Stock Gains Momentum With Key Clinical Trial Update

    Alterity (ATHE) Stock Gains Momentum With Key Clinical Trial Update

    As of the most recent check, Alterity Therapeutics Limited’s (NASDAQ: ATHE) stock was up 36.09%, trading at $2.17 on the US stock charts. The news of a significant success in its ATH434-201 Phase 2 clinical study triggered the spike in ATHE shares. This milestone marks the completion of clinical evaluations for the last enrolled patient, propelling the company closer to revealing its topline results, anticipated in late January or early February 2025.

    Trial Goals and Overview

    To evaluate the safety and efficacy of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurological condition, a randomized, double-blind, placebo-controlled study known as the ATH434-201 Phase 2 trial was developed. Alterity was aiming assessing the impact of the drug on neuroimaging and protein biomarkers, such as aggregating α-synuclein and brain iron, which are significant in MSA pathogenesis.

    Additionally, clinical endpoints, safety, pharmacokinetics, and motor activities monitored via wearable sensors form part of the comprehensive evaluation. 77 volunteers were recruited for the experiment and randomly randomized to receive either a placebo or one of two dosage levels of ATH434. Every participant received therapy for a full year, which yielded useful information for the planning of a conclusive Phase 3 study.

    Advancing Toward Data Analysis

    With the final patient visit completed, Alterity Therapeutics is now focused on the critical process of cleaning and locking the database. This step will enable the reporting of topline data early next year, a milestone eagerly awaited by stakeholders in the MSA community. The trial’s completion reflects the collaborative efforts of clinical sites, physicians, and patients worldwide, highlighting the strong interest in finding a potential treatment for this debilitating disease.

    Implications for Future Research

    The ATH434-201 trial represents a significant stride in Alterity’s mission to address MSA. By targeting biomarkers associated with disease progression, the study aims to provide robust evidence for ATH434’s therapeutic potential. The findings from this trial will lay the foundation for designing a Phase 3 study, bringing the company closer to a potential breakthrough in the treatment of MSA.

  • What Caused The Alterity (ATHE) Stock To Fell Before Market Opens Today?

    Alterity Therapeutics Limited (ATHE) stock was down -8.00 percent at $1.62 at the last check in pre-market trading. ATHE stock closed Friday session at $1.75, down -18.22% or $0.39. Price of Alterity stock ranged between $1.59 and $1.89. A total of 22.72 million securities were exchanged, a volume greater than ATHE’s YTD volume of 3.29 million and above its 50-day daily volume of 5.76 million.

    The ATHE stock has gained 204.37% in the past 12 months, and it has gained 28.67% in the last week. ATHE stock has gained 30.60% over the last six months and has gained 20.69% over the last three months. After gaining on last Thursday for grant of a new patent, ATHE stock has been consolidating.

    ATHE was granted a patent, what was it?

    ATH434, an early candidate from Alterity, is the first of a new generation of small molecules designed to suppress the formation of pathological proteins that result in neurodegeneration. As ATH434 decreases abnormal brain iron imbalance by preventing the abnormal accumulation of α-synuclein in animal models of disease, it can reduce symptoms of Parkinson’s disease. ATHE’s lead candidate is therefore well suited for treating Parkinson’s disease as well as atypical Parkinsonisms like Multiple System Atrophy (MSA). ATHE has been granted Orphan designation by the US FDA and the European Commission for ATH434 to treat MSA.

    On Thursday, Alterity announced that the United States Patent and Trademark (USPTO) had awarded it a composition of matter patent.

    • ATHE has patented a technology that reroutes excess iron in the nervous system through a new class of iron chaperones, a technology developed by the company.
    • ATHE’s patent illustrates the structure of a small molecule drug candidate that is capable of crossing the blood brain barrier and directly attacking the source of neuropathology.
    • Several important neurodegenerative diseases, including Alzheimer’s and Parkinson’s, have been linked to excess iron in the brain.
    • The USPTO granted the patent, entitled “Compounds for and Methods of Treating Diseases,” following expedited review.
    • More than 150 novel pharmaceutical substances are covered that redistribute labile iron, which is implicated in many neurodegenerative disorders.

    ATHE’s further plans:

    Alterity (ATHE ) expects to start the Phase 2 early next year with its lead clinical candidate ATH434. An experimental small molecule drug called ATH434 is being developed to treat Multiple System Atrophy (MSA), an atypical form of Parkinson’s disease in which iron promotes α-synuclein aggregation.

    In tandem with ATHE’s Phase 2 study results, scientific investigation of ATH434 will enhance the development and optimization of new compounds from the new patent. ATHE will be well-positioned to develop and commercialize drugs for significant neurodegenerative diseases as a result of the patent.

  • Alterity Therapeutics Ltd. (ATHE) stock surged in the premarket trading session; here’s why

    In the premarket trading session, Alterity Therapeutics Limited (ATHE) has advanced by 3.85% to the price of $1.35 at the last check. ATHE stock had previously closed the session gaining 1.56% at $1.30. ATHE stock’s share price had traded between $1.26 and $1.30. ATHE stock traded 86997.0 shares. In the past week, ATHE’s shares have shed by -5.11%, while in the last month the shares added 1.56%.

    Atlerity Therapeutics’ focuses on the treatment of Parkinson disease

    Alterity Therapeutics is a biotechnology firm that specifically focuses on the discovering, designing and developing of treatments and therapy for the unmet needs of the health market. Alterity specifically focuses on developing a platform for the treatment of Parkinsonian’s disease as well as other neurodegenerative diseases. The company operates in Australia and is established in Melbourne. Founded in 1997, Alterity Therapeutics Limited was known previously as Prana Biotechnology Limited until April 2019. The main investigational candidate of the company includes ATH434 – a treatment for Parkinson’s disease- which has passed the Phase I clinical trial tests. Furthermore, Alterity is also producing antimicrobial agents such as PBT2.

    The third quarter Fiscal year 2021 report for ATHE stock shows expected growth and progress

    The company’s profile is in-line with the company’s own as well as analyst’s expectations and predictions of its financial performances. Furthermore, the company is also on track with the progress and preparation in clinical study operational phases.

    During the quarter, Alterity has made significant advances in the phase II trial of the lead candidate drug known as ATH434 which is being developed for Multiple System Atrophy (MSA) patients. The company mainly focused its efforts the conduction of bioMUSE Natural History study that is being done on MSA patients. The study will be conducted at Vanderbilt university medical center and provide insight on the design and blueprint of the phase II study of ATH434which is planned to start in this year later. The investigation has now enlisted 80% of the first objective populace and the organization is assessing the plausibility to grow enlistment.

    The organization’s money position was $32.8M with operational money surges of $5M, in accordance with organization assumptions and reflecting continuous groundwork for the Phase 2 clinical preliminary for Alterity’s lead drug up-and-comer ATH434 in Multiple System Atrophy (MSA) patients.

    The company is strengthening its profile at investments and by regularly participating in scientific and clinical conferences. The largest health conference hosted by JP Morgan also became the point for presenting the company, in the satellite event known as Biotech Showcase. January and March were both months in which the CEO of Alterity David Stamler presented poster presentations to introduce their lead candidate in HC Wainwright. Stamler was appointed the CEO of the company in January. Furthermore, the company was granted US$495,000 by Michael J. Fox Foundation to assess the pharmacologic profile of ATH434 to decide the ideal dosage of the medication in future Parkinson’s illness clinical preliminaries. It was the second award the organization has gotten from the Michael J. Fox Foundation for ATH434.

  • What changed for these 46 stocks in Pre Market Session?

    What changed for these 46 stocks in Pre Market Session?

    Alterity Therapeutics Limited (ATHE) stock plunged -10.31% to $2.0 in the pre-market trading after the company announced the approval of a US patent for the next generation.

    Cinedigm Corp. (NASDAQ: CIDM) shares are trading down -4.55% at $0.525 at the time of writing after it posted Second Quarter Fiscal 2021 Earnings. The company’s 52-week range was noted as $0.25 to $6.00. Analysts have a consensus price target of $3.50.

    iBio Inc. (IBIO) tumbled over -2.34% at $1.67 in pre-market trading today as the Company revealed fiscal first quarter 2021 Financial results and provides a business update.

    CBAK Energy Technology Inc. (CBAT), an Electrical Equipment & Parts company, dropped about -7.4% at $9.01 in pre-market trading Wednesday.

    Comstock Mining Inc. (LODE) stock moved down -1.96 percent to $1.0 in the pre-market trading as it revealed to Host Earnings Call.

    CureVac N.V. (CVAC) lost over -3.01% at $74.19 in pre-market trading Wednesday 18 November 2020 after the news that the Company has established a European-based network to ramp Up manufacturing of its COVID-19 vaccine candidate, CVnCoV.

    Oncternal Therapeutics Inc. (ONCT) is down more than -24.88% at $3.11 in pre-market hours Wednesday 18 November 2020 as the Company increases previously revealed bought deal to $22.5 million. The stock had dropped over -9.41% to $4.14 in the last trading session.

    Before the trading started on 18 November 2020, New Concept Energy Inc. (GBR) is down -11.38% to reach $1.48 after the firm announced its Q3, 2020 results. It has been trading in a 52-week range of $0.55 to $2.19.

    Polar Power Inc. (POLA) stock plunged -7.25% to $3.07 in the pre-market trading. The most recent rating by ROTH Capital, on November 07, 2017, is at a Neutral.

    Trinity Biotech plc (NASDAQ: TRIB) shares are trading down 0.0% at $2.9 at the time of writing. The company’s 52-week range was noted as $0.56 to $3.35 as the company set to Host an Earnings Call.

    So-Young International Inc. (SY) grew over 4.65% at $13.5 in pre-market trading today as the company said it is going to report its earnings to result on November 25, 2020.

    BioNTech SE (BNTX), a Biotechnology company, rose about 4.22% at $90.6 in pre-market trading Wednesday after the report that Pfizer and BioNTech planned to file as vaccine proves 95% effective.

    Sunworks Inc. (SUNW) stock moved down -4.91 percent to $3.68 in the pre-market trading after the Company revealed that the proposed merger with the Peck Company Holdings, Inc. failed to secure stockholder approval.

    Sundial Growers Inc. (SNDL) lost over -3.04% at $0.2424 in pre-market trading Wednesday 18 November 2020 following the announcement of its third-quarter earnings results.

    Tuniu Corporation (TOUR) is up more than 1.04% at $1.95 in pre-market hours Wednesday 18 November 2020. The stock had dropped over -3.98% to $1.93 in the last trading session.

    Before the trading started on 18 November 2020, Taiwan Semiconductor Manufacturing Company Limited (TSM) is up 3.22% to reach $98.79 following the report that Samsung heats up chip wars with the claim that it can catch TSMC by 2022. It has been trading in a 52-week range of $42.70 to $102.44.

    Hill International Inc. (HIL) stock plunged -5.49% to $1.55 in the pre-market trading as the company said that CEO Raouf Ghali and CFO Todd Weintraub are scheduled to present at the following investor conferences during the month of November.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are trading down -4.77% at $0.5615 at the time of writing after the preliminary results following vaccination of non-human primates with TNX-1800 a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 spike protein after vaccination. The company’s 52-week range was noted as $0.39 to $2.46. Analysts have a consensus price target of $4.

    Genius Brands International Inc. (GNUS) tumbled over -3.42% at $1.13 in pre-market trading today after the company revealed strategic takeover of ChizComm Ltd. and ChizComm Beacon Media.

    Medley Management Inc. (MDLY), an Asset Management company, rose about 33.73% at $9.0 in pre-market trading Wednesday announced third-quarter earnings results.

    China SXT Pharmaceuticals Inc. (SXTC) stock moved down -3.59 percent to $0.2603 in the pre-market trading.

    Camtek Ltd. (CAMT) lost over -3.64% at $19.05 in pre-market trading Wednesday 18 November 2020 following the news of the commencement of a proposed underwritten public offering of three million ordinary shares.

    Cellectis S.A. (CLLS) is up more than 5.58% at $20.8 in pre-market hours Wednesday 18 November 2020, after the firm announced the appointment of Kyung Nam-Wortman as Cellectis’ Executive Vice President, Chief Human Resources Officer. The stock had dropped over -1.79% to $19.70 in the last trading session.

    Before the trading started on 18 November 2020, TechnipFMC plc (FTI) is up 4.34% to reach $8.42 after the Company received notice to proceed with the EPC contract for Sempra LNG’s and IEnova’s Energía Costa Azul LNG facility. It has been trading in a 52-week range of $4.49 to $21.84.

    Li Auto Inc. (LI) stock soared 3.17% to $36.16 in the pre-market trading after the Company revealed the 3rd quarter of 2020 Earnings results. The most recent rating by Citigroup, on November 16, 2020, is at a Buy.

    BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) shares are trading down -2.47% at $2.76 at the time of writing. The company’s 52-week range was noted as $2.35 to $62.00.

    Neptune Wellness Solutions Inc. (NEPT) tumbled over -2.63% at $1.85 in pre-market trading today after the company posted 2nd quarter loss and missed the predictions.

    Livent Corporation (LTHM), a Specialty Chemicals company, rose about 4.19% at $15.9 in pre-market trading Wednesday following the report of Analysts revised their forecast after disappointing Earnings.

    Micro Focus International plc (MFGP) stock moved up 29.73 percent to $4.8 in the pre-market trading.

    Houghton Mifflin Harcourt Company (HMHC) gained over 5.63% at $3.0 in pre-market trading Wednesday 18 November 2020 after the Company announced financial results for the quarter ended September 30, 2020. The Company revealed its plan to explore the potential sale of HMH Books & Media, its Consumer Publishing business.

    Acasti Pharma Inc. (ACST) is up more than 3.81% at $0.218 in pre-market hours Wednesday 18 November 2020 as the Company offered a business update for Q2, 2020. The stock had jumped over 0.77% to $0.21 in the last trading session.

    Before the trading started on 18 November 2020, Canaan Inc. (CAN) is up 8.73% to reach $3.61. It has been trading in a 52-week range of $1.76 to $13.00.

    VAALCO Energy Inc. (EGY) stock soared 45.1% to $1.48 in pre-market trading.

    Liminal BioSciences Inc. (NASDAQ: LMNL) shares are trading up 11.37% at $4.31 at the time of writing posted third-quarter results. The company’s 52-week range was noted as $3.51 to $31.45.

    Carver Bancorp Inc. (CARV) grew over 3.89% at $6.95 in pre-market trading today.

    Vaxart Inc. (VXRT), a Biotechnology company, dropped about -2.47% at $5.53 in pre-market trading Wednesday after it publicized that it is set to host a Key Opinion Leader (KOL) panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020, at 12pm Eastern Time.

    SCWorx Corp. (WORX) stock moved down -3.64 percent to $1.06 in the pre-market trading.

    Sunoco LP (SUN) lost over -7.0% at $27.11 in pre-market trading Wednesday 18 November 2020 as the Company gained above 5% as Q3 Earnings topped predictions.

    NIO Limited (NIO) is up more than 3.78% at $48.35 in pre-market hours Wednesday 18 November 2020 as the Company revealed its Q3 loss less than expected, whiles sales topped predictions. The stock had jumped over 2.22% to $46.59 in the last trading session.

    Before the trading started on 18 November 2020, Ocugen Inc. (OCGN) is up 4.27% to reach $0.3029 as Company recently revealed Q3 results. It has been trading in a 52-week range of $0.17 to $0.96.

    Weidai Ltd. (WEI) stock soared 9.4% to $1.63 in the pre-market trading after the report that the Company regained compliance after receipt of NYSE Non-compliance letter regarding ADS trading price on October 20, 2020. The most recent rating by Morgan Stanley, on January 21, 2020, is at an Underweight.

    Magnolia Oil & Gas Corporation (NYSE: MGY) shares are trading up 2.99% at $6.2 at the time of writing after the Company missed Earnings predictions. The company’s 52-week range was noted as $3.23 to $13.28.

    Waitr Holdings Inc. (WTRH) grew over 13.68% at $3.24 in pre-market trading today as the Company beat the Earnings outlook.

    Norwegian Cruise Line Holdings Ltd. (NCLH), a Travel Services company, dropped about -6.17% at $20.7 in pre-market trading Wednesday after the company revealed the pricing of 40,000,000 ordinary shares.

    IZEA Worldwide Inc. (IZEA) stock moved up 5.49 percent to $0.77 in the pre-market trading as it revealed Q3 financial results.

    The Boeing Company (BA) gained over 3.53% at $217.46 in pre-market trading Wednesday 18 November 2020 after the report that Boeing’s 737 Max cleared to fly in the US after crashes.

     

  • Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    CBAK Energy Technology Inc. (CBAT) stock soared 51.22% to $9.3 in pre-market trading.
    Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) shares are trading up 9.74% at $2.14 at the time of writing. The company’s 52-week range was noted as $0.89 to $2.69.
    Electra Meccanica Vehicles Corp. (SOLO) grew over 8.9% at $6.85 in pre-market trading today following analyst’s prediction that electric vehicles will overtake the global automotive sector in the near future.
    CPS Technologies Corporation (CPSH), an Electronic Components company, dropped about -8.72% at $1.57 in pre-market trading Monday.
    HighPoint Resources Corporation (HPR) stock moved up 77.39 percent to $6.67 in the pre-market trading after the news that Bonanza Creek Energy, Inc. BCEI and HighPoint Resources Corporation HPR have agreed on a merger worth $376 million.
    Navidea Biopharmaceuticals Inc. (NAVB) lost over -5.8% at $2.6 in pre-market trading Monday 16 November 2020 after the company announced its financial results for the third quarter and year-to-date 2020.
    Hall of Fame Resort & Entertainment Company (HOFV) is down more than -11.65% at $2.2 in pre-market hours Monday 16 November 2020 as the company and the NFL alumni association offered updates on the success of the inaugural NFL alumni academy. The stock had jumped over 22.06% to $2.49 in the last trading session.
    Before the trading started on 16 November 2020, GreenPower Motor Company Inc. (GP) is up 6.98% to reach $13.48 after the company posted its 2nd quarter financial results for 2021. It has been trading in a 52-week range of $0.82 to $23.45.
    Zomedica Pharmaceuticals Corp. (ZOM) stock plunged -7.07% to $0.088 in the pre-market trading as the plans to initiate commercialization on 30 March 2021 of its TRUFORMATM point-of-care diagnostic platform revealed.
    Polar Power Inc. (NASDAQ: POLA) shares are trading up 7.81% at $3.59 at the time of writing. Company’s 52-week range was noted as $0.95 to $6.56.
    Sino-Global Shipping America Ltd. (SINO) tumbled over -2.92% at $2.66 in pre-market trading today.
    Pinduoduo Inc. (PDD), an Internet Retail company, dropped about -1.78% at $148.59 in pre-market trading Monday as the firm unveils its Q3 results.
    Tellurian Inc. (TELL) stock moved down -4.51 percent to $0.9644 in the pre-market trading as the news appeared that the company is pondering new Asia gas deals After Petronet snub.
    9 Meters Biopharma Inc. (NMTR) lost over -3.58% at $0.8 in pre-market trading Monday 16 November 2020 as the company revealed financial results and business updates.
    Centennial Resource Development Inc. (CDEV) is down more than -2.88% at $0.741 in pre-market hours Monday 16 November 2020 after the company said Sean R. Smith, Chief Executive Officer, is set to attend the Bank of America Securities Global Energy Conference to be held virtually on Thursday. The stock had jumped over 9.14% to $0.76 in the last trading session.
    Before the trading started on 16 November 2020, Genius Brands International Inc. (GNUS) is up 7.38% to reach $1.31, after the company stated that it is set to host a conference call at 10:00 a.m. Eastern Time on Monday, November 16, 2020, to review major initiatives underway and recent developments. The stock has been trading in a 52-week range of $0.05 to $11.73.
    CureVac N.V. (CVAC) stock soared 8.38% to $81.5 in the pre-market trading after the report that the covid-19 vaccine could be a drug industry game-changer. The most recent rating by Jefferies, on September 08, 2020, is a Hold.
    Apple Hospitality REIT Inc. (NYSE: APLE) shares are trading down -2.83% at $12.02 at the time of writing after the company posted 3rd quarter results of operation. The company’s 52-week range was noted as $4.48 to $16.42. Analysts have a consensus price target of $13.
    Transocean Ltd. (RIG) tumbled over -3.7% at $1.04 in pre-market trading today as the company stock soared 53% since the earnings announcement.
    Cinedigm Corp. (CIDM), an Entertainment company, rose about 8.33% at $0.65 in pre-market trading Monday as the company has purchased North American distribution rights to 100 DAYS TO LIVE, a taut psychological thriller set in the world of suicide prevention and mental health.
    Range Resources Corporation (RRC) stock moved down -5.57 percent to $6.78 in pre-market trading as the company recently revealed disappointing earnings.
    UP Fintech Holding Limited (TIGR) gained over 11.9% at $6.02 in pre-market trading Monday 16 November 2020 as the capital market giant revealed that it will announce its Q3 results on November 23, 2020.
    Taubman Centers Inc. (TCO) is up more than 8.11% at $42.68 in pre-market hours Monday 16 November 2020 after the publication report that Simon Property and Taubman have finally agreed on a merger on a well-reduced price of $43.00 per share in cash. The stock had jumped over 5.53% to $39.48 in the last trading session.
    Before the trading started on 16 November 2020, Banco Bilbao Vizcaya Argentaria S.A. (BBVA) is up 15.24% to reach $4.31 after the announcement that PNC Financial Services Group Inc (NYSE: PNC) is set to take over Banco Bilbao Vizcaya Argentaria (BBVA) U.S. business in an $11 billion all-cash deal. The stock has been trading in a 52-week range of $2.49 to $5.80.
    Kandi Technologies Group Inc. (KNDI) stock soared 7.62% to $7.77 in the pre-market trading as the Company announced that It completed a registered direct offering of 9,404,392 shares of its securities at a sales price of $6.38 per share, raising about $60,000,000 in net gross proceeds to the Firm before deducting the selling agent’s fees and other expected offering expenditures incurred by the Company.
    Textainer Group Holdings Limited (NYSE: TGH) shares are trading down -5.5% at $15.65 at the time of writing after the company posted its third-quarter results. The company’s 52-week range was noted as $5.50 to $17.33. Analysts have a consensus price target of $18.
    Gulfport Energy Corporation (GPOR) tumbled over -45.61% at $0.13 in pre-market trading today after the company filed for bankruptcy.
    Akerman Corp. (KERN), a Health Information Services company, dropped about -3.46% at $2.79 in pre-market trading Monday after the company posted its earnings results.
    United States Antimony Corporation (UAMY) stock moved up 4.17 percent to $0.375 in the pre-market trading.
    ADiTx Therapeutics Inc. (ADTX) lost over -2.03% at $1.93 in pre-market trading Monday 16 November 2020 as the company offered the latest business updated as well as its fiscal quarterly report.
    Arbutus Biopharma Corporation (ABUS) is up more than 10.19% at $4.0 in pre-market hours Monday 16 November 2020 after the firm revealed presentation of phase 1a/1b clinical trial results for AB-729 in chronic hepatitis B subjects at the liver meeting digital experience, the American Association for the study of Liver Diseases meeting. The stock had jumped over 2.25% to $3.63 in the last trading session.
    Before the trading started on 16 November 2020, Ideanomics Inc. (IDEX) is up 31.31% to reach $1.3 after the company revealed the final agreement to take over Timios holding corps. It has been trading in a 52-week range of $0.28 to $3.98.
    Pacific Ethanol Inc. (PEIX) stock soared 4.71% to $6.0 in the pre-market trading as the company announced Q3 results. The most recent rating by BWS Financial, on September 22, 2020, is a Buy.
    CEL-SCI Corporation (AMEX: CVM) shares are trading up 10.5% at $14.0 at the time of writing. The company’s 52-week range was noted as $6.35 to $18.00. Analysts have a consensus price target of $18.
    AMC Entertainment Holdings Inc. (AMC) grew over 8.42% at $3.22 in pre-market trading today following news that Cinemark joins AMC in pursuing a shortened movie window.
    Sogou Inc. (SOGO), an Internet Content & Information company, dropped about -3.14% at $8.64 in pre-market trading Monday as the company unveiled its Q3, 2020 results.
    ObsEva SA (OBSV) stock moved up 18.84 percent to $2.46 in the pre-market trading as the company announced the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of laropiprant in preterm labor.
    Denison Mines Corp. (DNN) lost over -9.3% at $0.32 in pre-market trading Monday 16 November 2020 after the company announced the establishment of the At-The-Market Program.
    Pyxis Tankers Inc. (PXS) is down more than -25.74% at $0.8763 in pre-market hours Monday 16 November 2020 as the company announced results for its 3rd quarter and year to date. The stock had dropped over 0.00% to $1.18 in the last trading session.
    Before the trading started on 16 November 2020, Qutoutiao Inc. (QTT) is down -2.13% to reach $2.3. It has been trading in a 52-week range of $2.12 to $6.55.
    Uxin Limited (UXIN) stock plunged -3.85% to $1.0 in the pre-market trading after the news that the company’s Net Promoter Score (NPS) increases to 30 during the quarter ended September 30, 2020. The most recent rating by JP Morgan, on October 23, 2019, is at a Neutral.
    VistaGen Therapeutics Inc. (NASDAQ: VTGN) shares are trading down -2.13% at $0.6851 at the time of writing. The company’s 52-week range was noted as $0.29 to $1.15. Analysts have a consensus price target of $6.
    Sypris Solutions Inc. (SYPR), an Auto Parts company, dropped about -3.6% at $1.34 in pre-market trading Monday after the company announced its 3rd quarter earnings results.
    Alterity Therapeutics Limited (ATHE) stock moved up 169.57 percent to $3.1 in the pre-market trading.